Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of JNJ-27018966 in diarrhea-predominant irritable bowel syndrome
2012-001600-38Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing JNJ-27018966 with Placebo (2 arms). Primary endpoints: Clinical response after 12 weeks of treatment, Pain responder status and 1 more. Started Jun 2012; status: completed.
02
Drugs
eluxadoline
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2012-001600-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001600-38.